thyssenkrupp nucera AG & Co. KGaA: Preliminary figures for FY 2025/ 26: Order intake above previous year, free cash flow positive; EBIT below guidance due to additional project costs in the gH2 segment
Published on 11/20/2026 at 18:18 | dgap, AD HOC NEWS| EQS-Ad-hoc: thyssenkrupp nucera AG & Co. KGaA / Key word(s): Results / Full year/Forecast / Full year thyssenkrupp nucera AG & Co. KGaA: Preliminary figures for FY 2025/26: Order intake above previous year, free cash flow positive; EBIT below guidance due to additional project costs in the gH2 segment 20-Nov-2026 / 18:18 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. thyssenkrupp nucera AG & Co. KGaA: Preliminary figures for FY 2025/26 – Order intake above previous year, free cash flow positive – EBIT below guidance due to additional project costs in the gH2 segment thyssenkrupp nucera AG & Co. KGaA (“thyssenkrupp nucera”) increased order intake in both segments in the past fiscal year 2025/26 and once again achieved positive free cash flow. The focus was on consistently executing the order backlog, securing new large orders in both segments, and further optimizing the cost structure. At the same time, one-off effects in the green hydrogen (gH2) business weighed on sales and earnings. Based on preliminary, unaudited figures, thyssenkrupp nucera expects Group sales of approximately €450 million for fiscal year 2025/26 (2024/25: €845 million). This is at the lower end of the previous sales guidance of €450 million to €500 million. Group EBIT is expected to amount to €–136 million (2024/25: €2 million), which is below the previous guidance of €–105 million to €–75 million. The deviation from the previous EBIT guidance results from additional expenses of just under €40 million in the fourth quarter of 2025/26. These are primarily related to the ongoing completion and commissioning of the first plants in the gH2 segment and primarily concern the rectification of supplier-related defects in components outside the electrolysis cells. In fiscal year 2025/26, EBIT included total charges from one-off effects of around €110 million, primarily due to one-time additional expenses in new-build projects and the impairment of the SOEC pilot plant in the gH2 segment. In accordance with IFRS 15, the additional expenses lead to an accounting-related reduction in the percentage of completion of new-build projects and thus also to a technical negative sales effect, which will be partially reversed in fiscal year 2026/27 and thereby support sales performance. Sales in the gH2 segment are expected to amount to €84 million in fiscal year 2025/26 (2024/25: €459 million). The previous sales guidance was €100 million to €130 million. EBIT in this segment decreased to an expected €–197 million (2024/25: €–56 million). The previous EBIT guidance was €–155 million to €–135 million. The Chlor-Alkali (CA) segment meets the sales and EBIT guidance. Sales are expected to amount to approximately €365 million (2024/25: €386 million). EBIT is expected to increase to €61 million (2024/25: €58 million) and is therefore at the upper end of the guidance range. The EBIT margin in the CA segment is around 17% and thus above the previous year (2024/25: 15%). Order intake in fiscal year 2025/26 increased by around 60% to an expected €559 million (2024/25: €348 million). The guidance for Group order intake is therefore also met. Of this, around €196 million is attributable to the gH2 segment (2024/25: €26 million) and around €362 million to the CA segment (2024/25: €322 million). The increase in order intake provides a basis for sales growth in fiscal year 2026/27. Other financial figures Net income is expected to amount to €–145 million (2024/25: €5 million); earnings per share are accordingly expected to be €–1.15 (2024/2025: €0.04). thyssenkrupp nucera generated positive free cash flow of €16 million in the past fiscal year 2025/26 (2024/25: €11 million) and thus continues to finance itself from its operating activities. All published figures and statements are preliminary and unaudited. The detailed Q4/FY 2025/26 results will be published in the 2025/26 Annual Report on 16 December 2026 at 7:00 a.m. CET. Financial figures: Explanations of the financial performance indicators used can be found in the 2024/25 Annual Report of thyssenkrupp nucera on pages 31 to 32, available at the following link: https://investors.thyssenkrupp-nucera.com/investors/publications Person making the notification: Dr. Hendrik Finger, Head of Investor Relations, thyssenkrupp nucera AG & Co. KGaA End of Inside Information 20-Nov-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News |
| Language: | English |
| Company: | thyssenkrupp nucera AG & Co. KGaA |
| Freie-Vogel-Str. 385 a | |
| 44269 Dortmund | |
| Germany | |
| Phone: | +49 231-22972-7100 |
| E-mail: | info@thyssenkrupp-nucera.com |
| Internet: | www.thyssenkrupp-nucera.com |
| ISIN: | DE000NCA0001 |
| WKN: | NCA000 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| LEI Code: | 549300T0K3CI2C25SC77 |
| EQS News ID: | 2439838 |
| End of Announcement | EQS News Service |
| |
2439838 20-Nov-2026 CET/CEST
en | DE000NCA0001 | THYSSENKRUPP NUCERA AG & CO. KGAA | boerse | 70540794 |
